We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Regeneron Pharmaceuticals (REGN - Free Report) , Celgene Corporation , Sanofi (SNY - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Biotech Stock Roundup: CELG, REGN, VKTX and More
Major pipeline and regulatory updates dominated biotech sector headlines over the past week. Viking Therapeutics’ fatty liver drug succeeded in a phase II study. Both Regeneron Pharmaceuticals and Celgene Corporation presented positive results at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France.
Recap of the Week’s Most Important Stories:
Viking Soars on Successful Fatty Liver Drug Study: Shares of Viking Therapeutics soared after the company announced positive top-line results from a 12-week phase II study on its novel liver-selective thyroid receptor beta agonist, VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). The study achieved its primary endpoint, as statistically significant reductions in LDL-C were observed in patients receiving VK2809. In the study, 57% to 60% median liver fat reduction was observed in VK2809-treated patients. In addition, the trial's secondary endpoint was achieved with VK2809-treated patients experiencing statistically significant reductions in liver fat content compared with placebo.
Celgene Presents Data on Psoriasis Drug: Celgene announced encouraging results from two post hoc sub-analyses of clinical trials for psoriasis drug, Otezla at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. The data indicate that usage of Otezla resulted in meaningful improvements in outcomes important to patients with moderate to severe plaque psoriasis, which may not be captured by common measures of treatment efficacy that focus only on skin clearance ,such as Psoriasis Area Severity Index (PASI) 75. Meaningful improvements in skin, itch and quality-of-life measures were observed in treatment with Otezla. In addition, a separate post hoc sub-analysis of data from the phase III ESTEEM 1 and 2 and phase IV UNVEIL trials showed improvement in areas such as scalp and nails with Otezla compared to placebo.
Regeneron/Sanofi Report Positive Data on Dupixent: Regeneron Pharmaceuticals and partner Sanofi presented positive detailed results from a phase III trial on Dupixent for atopic dermatitis in adolescents at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. The phase III trial evaluated the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis. Per the company, this is the first phase III trial of a biologic in this patient population. The trial enrolled 251 patients who were 12 years to 17 years of age with moderate-to-severe atopic dermatitis and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable. The results show that Dupixent monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients.
Earlier, Regeneron had announced that the FDA accepted for review the supplemental Biologics License Application (sBLA) of flagship ophthalmology drug, Eylea injection for the treatment of diabetic retinopathy (DR) and set a target action date of May 13, 2019. The sBLA submission is based on positive results from the phase III PANORAMA trial announced in Mar 2018.
Gilead Collaborates With Precision Biosciences: Gilead Sciences, Inc. entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter’s gene editing platform ARCUS. Per the agreement, Precision will be responsible for developing, formulating and preclinical evaluation of the investigational nucleases while Gilead will take care of clinical development of any therapies emerging from the deal and commercialization of potential therapies. Gilead will fund the entire research and development program. Gilead is entitled to pay up to $445 million to Precision BioSciences as potential milestone payments and tiered royalties up to the mid-teens on commercial sales.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
For Immediate Release
Chicago, IL – September 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Regeneron Pharmaceuticals (REGN - Free Report) , Celgene Corporation , Sanofi (SNY - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
Biotech Stock Roundup: CELG, REGN, VKTX and More
Major pipeline and regulatory updates dominated biotech sector headlines over the past week. Viking Therapeutics’ fatty liver drug succeeded in a phase II study. Both Regeneron Pharmaceuticals and Celgene Corporation presented positive results at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France.
Recap of the Week’s Most Important Stories:
Viking Soars on Successful Fatty Liver Drug Study: Shares of Viking Therapeutics soared after the company announced positive top-line results from a 12-week phase II study on its novel liver-selective thyroid receptor beta agonist, VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). The study achieved its primary endpoint, as statistically significant reductions in LDL-C were observed in patients receiving VK2809. In the study, 57% to 60% median liver fat reduction was observed in VK2809-treated patients. In addition, the trial's secondary endpoint was achieved with VK2809-treated patients experiencing statistically significant reductions in liver fat content compared with placebo.
Celgene Presents Data on Psoriasis Drug: Celgene announced encouraging results from two post hoc sub-analyses of clinical trials for psoriasis drug, Otezla at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. The data indicate that usage of Otezla resulted in meaningful improvements in outcomes important to patients with moderate to severe plaque psoriasis, which may not be captured by common measures of treatment efficacy that focus only on skin clearance ,such as Psoriasis Area Severity Index (PASI) 75. Meaningful improvements in skin, itch and quality-of-life measures were observed in treatment with Otezla. In addition, a separate post hoc sub-analysis of data from the phase III ESTEEM 1 and 2 and phase IV UNVEIL trials showed improvement in areas such as scalp and nails with Otezla compared to placebo.
Regeneron/Sanofi Report Positive Data on Dupixent: Regeneron Pharmaceuticals and partner Sanofi presented positive detailed results from a phase III trial on Dupixent for atopic dermatitis in adolescents at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. The phase III trial evaluated the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis. Per the company, this is the first phase III trial of a biologic in this patient population. The trial enrolled 251 patients who were 12 years to 17 years of age with moderate-to-severe atopic dermatitis and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable. The results show that Dupixent monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients.
Earlier, Regeneron had announced that the FDA accepted for review the supplemental Biologics License Application (sBLA) of flagship ophthalmology drug, Eylea injection for the treatment of diabetic retinopathy (DR) and set a target action date of May 13, 2019. The sBLA submission is based on positive results from the phase III PANORAMA trial announced in Mar 2018.
Gilead Collaborates With Precision Biosciences: Gilead Sciences, Inc. entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter’s gene editing platform ARCUS. Per the agreement, Precision will be responsible for developing, formulating and preclinical evaluation of the investigational nucleases while Gilead will take care of clinical development of any therapies emerging from the deal and commercialization of potential therapies. Gilead will fund the entire research and development program. Gilead is entitled to pay up to $445 million to Precision BioSciences as potential milestone payments and tiered royalties up to the mid-teens on commercial sales.
Gilead currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.